Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer

Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology. The INNOVATE trial was a prospective, single-arm …

Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update

Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018 Submission of local coverage determination reconsideration request to the durable medical equipment Medicare administrative contractors following June CMS announcement of new payment rules for durable medical equipment products STELLAR data in …

Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society

The IEEE Engineering in Medicine and Biology Society’s 40th International Conference is the first conference in which a scientific track will be devoted to Tumor Treating Fields, increasing the awareness of Novocure’s proprietary cancer therapy among the scientific community The conference will feature seven oral presentations on Tumor Treating Fields ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure …

Novocure Appoints Pritesh Shah as Chief Commercial Officer

With extensive experience in oncology, Pritesh Shah will be responsible for Novocure’s commercial strategy worldwide ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Pritesh Shah has been appointed as Novocure’s Chief Commercial Officer, reporting to Novocure’s Chief Executive Officer Asaf Danziger. In this role, Mr. Shah will be responsible for the development and execution …

Novocure to Report Second Quarter 2018 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2018, …

Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer …

Novocure Announces Changes to Its Board of Directors

Former Medivation CEO, Dr. David T. Hung, elected to board of directors Former Avon CEO, Sherilyn D. McCoy, elected to board of directors Gert Lennart Perlhagen retiring after 15 years of service ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced changes to its board of directors. Dr. David T. Hung and Sherilyn D. McCoy, …

Novocure Reports First Quarter 2018 Financial Results and Provides Company Update

2,009 active patients at March 31, 2018, an increase of 59 percent versus March 31, 2017 Delivered quarterly net revenues of $52.1 million, representing 49 percent growth versus the first quarter 2017 NCCN guidelines updated to recommend Optune in combination with temozolomide as a category 1 treatment for newly diagnosed glioblastoma Positive topline results from …

Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma

Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints Novocure plans to submit a Humanitarian Device Exemption application to the FDA for approval ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today positive top-line results from its STELLAR phase 2 pilot trial in mesothelioma demonstrating clinically meaningful improvements in overall …